In the nervous system, CRISPR-Cas9 nanocomplexes were delivered in vivo to the mouse hippocampus, and were effective in targeting Bace1 in postmitotic neurons of the adult mouse brain, suppressing amyloid beta-associated pathologies in mouse models of AD [47]. Here, BACE1 is linked to Alzheimer disease.